Investec Asset Management LTD lowered its position in Mednax, Inc (NYSE:MD) by 4.0% during the fourth quarter, Holdings Channel reports. The fund owned 1,178,689 shares of the company’s stock after selling 49,364 shares during the period. Investec Asset Management LTD owned approximately 1.27% of Mednax worth $78,571,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors have also recently bought and sold shares of MD. First Bank & Trust purchased a new position in Mednax during the fourth quarter worth about $175,000. 1st Global Advisors Inc. purchased a new position in Mednax during the third quarter worth about $205,000. Bronfman E.L. Rothschild L.P. increased its position in Mednax by 8.3% in the third quarter. Bronfman E.L. Rothschild L.P. now owns 3,209 shares of the company’s stock worth $213,000 after buying an additional 247 shares during the last quarter. Capital Fund Management S.A. increased its position in Mednax by 6.0% in the third quarter. Capital Fund Management S.A. now owns 3,721 shares of the company’s stock worth $247,000 after buying an additional 210 shares during the last quarter. Finally, Argent Capital Management LLC increased its position in Mednax by 9.2% in the third quarter. Argent Capital Management LLC now owns 3,900 shares of the company’s stock worth $258,000 after buying an additional 330 shares during the last quarter. Institutional investors and hedge funds own 98.45% of the company’s stock.
Mednax, Inc (NYSE:MD) traded up 0.58% during mid-day trading on Friday, reaching $68.00. The company had a trading volume of 871,658 shares. Mednax, Inc has a one year low of $59.36 and a one year high of $76.96. The company’s 50-day moving average is $68.57 and its 200-day moving average is $66.21. The stock has a market capitalization of $6.35 billion, a PE ratio of 19.48 and a beta of 0.67.
Mednax (NYSE:MD) last posted its quarterly earnings results on Tuesday, February 7th. The company reported $1.00 earnings per share for the quarter, missing analysts’ consensus estimates of $1.06 by $0.06. Mednax had a return on equity of 13.59% and a net margin of 10.21%. The firm had revenue of $831 million for the quarter, compared to analyst estimates of $842.15 million. During the same period last year, the company posted $1.13 earnings per share. The firm’s quarterly revenue was up 12.0% compared to the same quarter last year. Equities research analysts anticipate that Mednax, Inc will post $4.26 earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: This piece of content was first reported by sleekmoney and is the sole property of of sleekmoney. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of US & international trademark & copyright law. The correct version of this piece of content can be viewed at http://sleekmoney.com/investec-asset-management-ltd-cuts-stake-in-mednax-inc-md/1655135.html.
MD has been the subject of a number of research reports. Mizuho decreased their price objective on Mednax from $79.00 to $69.00 and set a “buy” rating for the company in a report on Friday, October 28th. Zacks Investment Research upgraded Mednax from a “hold” rating to a “buy” rating and set a $77.00 price target for the company in a research note on Thursday, February 2nd. Jefferies Group LLC restated a “hold” rating and issued a $63.00 price target on shares of Mednax in a research note on Wednesday. They noted that the move was a valuation call. Raymond James Financial, Inc. downgraded Mednax from an “outperform” rating to a “market perform” rating in a research note on Thursday, October 27th. Finally, Goldman Sachs Group, Inc. (The) started coverage on Mednax in a research note on Friday, December 9th. They issued a “neutral” rating and a $66.00 price target for the company. Seven equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $71.56.
In related news, Director Md Pascal J. Goldschmidt acquired 2,100 shares of the firm’s stock in a transaction on Wednesday, December 7th. The stock was purchased at an average cost of $66.52 per share, with a total value of $139,692.00. Following the acquisition, the director now owns 13,355 shares of the company’s stock, valued at approximately $888,374.60. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Md Carlo A. Waldemar sold 5,334 shares of the business’s stock in a transaction that occurred on Thursday, February 9th. The stock was sold at an average price of $67.90, for a total value of $362,178.60. Following the sale, the director now directly owns 16,589 shares of the company’s stock, valued at $1,126,393.10. The disclosure for this sale can be found here. 2.40% of the stock is currently owned by corporate insiders.
Mednax Company Profile
MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. The Company’s national network consists of approximately 3,240 affiliated physicians, including approximately 1,100 physicians who provide neonatal clinical care, in over 30 states and Puerto Rico, within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.
Want to see what other hedge funds are holding MD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mednax, Inc (NYSE:MD).
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/investec-asset-management-ltd-cuts-stake-in-mednax-inc-md/1655135.html
Receive News & Ratings for Mednax Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax Inc and related companies with MarketBeat.com's FREE daily email newsletter.